Identification of Genetic, Phenotypic, Clinical, Biological and Histological Factors Differentiating Patients With Ovarian Cancer Who Are Refractory to Platinum-based Therapy From Patients Defined as Long-term Responders to Platinum-based Therapy
NCT07361471 · NA · Clermont-Ferrand, PUY DE DOME, France
- Condition
- Ovarian Cancer
- Disease stage
- Stage I-IV
- Phase
- NA
- Study type
- GENETIC
- Intervention
- molecular analysis
- Age
- 18 Years to
- Gender
- Female
- Sponsor
- Centre Jean Perrin
- Research institution
- Centre Jean Perrin
- Facility
- Centre Jean Perrin
- Research center
- Centre Jean Perrin
Summary
After having constituted the ORTRAI cohort using the CONSORE database at the Jean PERRIN Center, the objective is to characterize the patients both clinically and biologically, histologically and genomically. The clinical and biological characterizations will allow us to confirm that our cohort is comparable with data from the literature. The complement of immunohistochemical and molecular analyses will provide more details on the differences between long-term patients responding to treatment and refractory patients.
Inclusion criteria
* Major patient, treated at the Jean Perrin Center, suffering from ovarian cancer at any stage and treated with platinum-based chemotherapy in the first line of treatment. * Corresponding to one of the two groups below: * Refractory group: patients progressing in the first therapeutic line of platinum-based chemotherapy. * Group of long-term responders: patients who have not progressed 5 years after the end of first-line platinum salt treatment * Affiliation to a social security scheme * Patient who signed the genetic consent form
Exclusion criteria
* Minor patient * Pregnant patient * Patient under guardianship or conservatorship * Patients who object to the collection of their medical/paramedical data * Patient for whom the center does not have biological material for genomic analysis (FFPE block) * Patient under administrative, judicial decision or AME (State Medical Aid)
Primary outcomes
Molecular anomalies retained after biological interpretation and allowing the differentiation of refractory patients from long-term responder patients.
Secondary outcomes
Phenotypic criteria differences between refactory patients and long responder patients; Clinical criteria differences between refactory patients and long responder patients; Biological criteria difference between refactory patients and long responder patients